Kjelsåsveien 168 B
283 articles with Nordic Nanovector
Reference is made to the minutes from Nordic Nanovector ASA's annual general meeting held on 28 April 2021 in Oslo, Norway.
Nordic Nanovector ASA announces its results for the first quarter 2021. A live webcast presentation by Nordic Nanovector's management team will take place at 08.30 CEST.
Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma
Nordic Nanovector ASA announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin® in combination with rituximab in second-line follicular lymphoma.
Nordic Nanovector ASA announces that it will report its results for the first quarter 2021 on Wednesday, 26 May 2021.
The Annual General Meeting of Nordic Nanovector ASA was held on 28 April 2021 in Oslo, Norway.
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2021 , at 14:00 hours CEST at Kjelsåsveien 168 B 0884 Oslo.
Nordic Nanovector ASA announces that its Nomination Committee has nominated Mrs Solveig Hellebust for election as a Non-executive Director at the Company's Annual General Meeting on 28 April 2021.
On 26 March 2021, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2020.
The Board of Directors of Nordic Nanovector ASA has on 26 March 2021 decided to grant 1,070,000 Performance Share Units to employees in accordance with the authorisation granted at the Annual General Meeting held on 10 June 2020.
Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer
Nordic Nanovector ASA announces the appointment of Peter L. Braun as Chief Executive Officer.
Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Carnegie's upcoming Nordic Virtual Healthcare Seminar 2021, taking place 9-12 March 2021.
Nordic Nanovector ASA announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 9 March at the 11th Annual World ADC Europe 2021 Digital event in the Discovery stream discussing the question: Should Payloads be Super-Potent?
Nordic Nanovector ASA announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic Nanovector's management team will take place at 08.30 CET.
Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma
Nordic Nanovector ASA provides an update on PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® in 3rd-line relapsed/refractory follicular lymphoma.
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2020 Results Presentation and Webcast
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2020 on Thursday, 18 February 2021 .
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB's 11th Annual Nordic Healthcare Conference, taking place on 15 December 2020.
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma
Nordic Nanovector ASA announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Nordic Nanovector ASA announces that the Company's ticker symbol on the Oslo Børs will change from 'NANO' to 'NANOV' and will be effective as of the start of trading on 30 November 2020.
Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial
Nordic Nanovector ASA announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 trial investigating safety and preliminary efficacy of Betalutin® in combination with rituximab in 2nd-line follicular lymphoma.